The Clinical Significance of Neurofilament Heavy Chain SMI-35 Examination in Patients with Neuromyelitis Optica

Xiang ZHANG,Xiangjun CHEN,Xiang LI,Jian QIAO,Yuehua GU

DOI: https://doi.org/10.3969/j.issn.1006-2963.2016.04.001

2016-01-01

Abstract:Objective To investigate the level and clinical significance of neurofilament heavy chain SMI-35 (NfHSMI-35 )in patients with neuromyelitis optica (NMO). Methods NfHSMI-35 levels were tested in sera of 27 NMO patients,20 multiple sclerosis (MS)patients and 26 healthy controls (HC)by ELISA method, AQP4-IgG levels were tested in all NMO patients. The NfHSMI-35 levels were compared among NMO,MS and HC groups and between AQP4-IgG-positive and AQP4-IgG-negative patients with NMO. The correlation among NfHSMI-35 levels and the involved spinal cord segments and Expanded Disability Status Scale (EDSS)were analyzed. Results The average NfHSMI-35 levels in sera of the NMO,MS and HC groups were (0.100±0.024), (0.082±0.012)and (0.064±0.021)ng/mL respectively. The average NfHSMI-35 levels in sera of the NMO and MS groups were higher than those of the HC group (P <0.05),while compared with the MS group,the level of NfHSMI-35 was higher in the NMO group (P <0.05). For NMO patients,there were no statistical significances of NfHSMI-35 levels in sera between AQP4-IgG-positive and AQP4-IgG-negative patients [(0.106±0.029)ng/mL vs. (0.091 ±0.013)ng/mL,P >0.05 ]. NfHSMI-35 levels had significant correlation with the involved spinal cord segments (r=0.556,P <0.01 )but not EDSS score (r =0.214,P >0.05 ). Conclusions NfHSMI-35 in sera may be considered as one biomarker of NMO and clinical monitoring index to differentiate NMO from MS, but further observation and research are still needed.